Opus Genetics (IRD) CFO Robert E. Gagnon Sells $50K of Stock
Key Points
- Robert E. Gagnon sold 14,000 shares at an average price of $3.55, reducing his holdings to 542,375 shares.
- As of October 27, 2026, Opus Genetics was trading around $3.46, below its 50-day moving average of $4.49.
- Analysts maintain a strong outlook on Opus Genetics, with a consensus rating of 'strong buy' and a mean price target of $13.47.
Since the trade, $IRD is down 0.3% to date (from the $3.47 close on Oct 23, 2026).
Get Opus Genetics text alerts
We text you when insiders, Congress, analysts or big funds move on $IRD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures
On October 23, 2026, Robert E. Gagnon, the Chief Financial Officer of Opus Genetics, Inc. (IRD), sold 14,000 shares at an average price of $3.55, totaling about $49,649. This sale was reported in a Form 4 filing with the SEC, and it marks a planned transaction, reducing Gagnon's stake by 2.52% to 542,375 shares.
IRD
Opus Genetics, Inc.
Other Institutional Activity in Opus Genetics
Caligan Partners, LP holds 6,077,084 shares, valued at about $21 million. Adage Capital Partners GP L.L.C. also maintains a significant position with 6,029,775 shares worth approximately $20.9 million. Meanwhile, Bios Capital Management, LP holds 3,683,429 shares, valued at about $12.7 million. Balyasny Asset Management LP increased its holdings by 369,913 shares, totaling 3,087,866 shares worth about $10.7 million. Nantahala Capital Management, LLC added 1,380,033 shares, now owning 3,061,359 shares valued at about $10.6 million.
Opus Genetics, Inc. Stock Up 4.2%
Opus Genetics closed at $3.47 on October 23, 2026, shortly before Gagnon's sale. As of October 27, 2026, the stock was recently trading around $3.46, which is below its 50-day moving average of $4.49 and significantly below its 52-week high of $7.07. This suggests the stock has seen a considerable decline from its peak.
Recent Earnings
Opus Genetics reported trailing twelve-month revenue of approximately $9.86 million. However, the company has faced challenges, with a year-over-year revenue growth rate of -73.8%. The next earnings report is scheduled for November 11, 2026.
Analysts Set New Price Targets
On October 22, 2026, Chardan Capital maintained a 'Buy' rating on Opus Genetics with a price target of $16.00. Earlier, on October 16, 2026, Citizens reiterated a 'Market Outperform' rating with a target of $17.00. Analysts remain optimistic, with a consensus rating of 'strong buy' and a mean price target of $13.47.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company based in Durham, NC. It focuses on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases. The company's leading candidates are in clinical trials, targeting specific retinal disorders.
Bottom Line
Investors should monitor Opus Genetics as it approaches its next earnings date on November 11, 2026. Gagnon's planned sale may reflect personal financial decisions rather than company performance. Analysts continue to express confidence in the stock's potential, with several maintaining strong ratings and price targets well above current levels.
Related Filing Alerts
Source: Robert E. Gagnon's Form 4 filing on $IRD (Oct 23, 2026). Written by software, not financial advice. How we make alerts